Stefan Knapp

Stefan Knapp

SGC Frankfurt

Knapp

Biography

Prof Stefan Knapp studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

Research Areas

My laboratory is interested in understanding molecular mechanisms that regulate protein function of key signalling molecules and how these mechanisms can be utilized for the development of highly selective and potent inhibitors (chemical probes). As a basis for this work we have generated a comprehensive set of high resolution crystal structures that cover most members of the protein family of interest. We are particularly interested in protein interactions module of the bromodomain family that specifically recognize ε-N-lysine acetylation motifs, a key event in the reading process of epigenetic marks. This effort generated several highly selective chemical probes targeting bromodomains. A second research focus is on protein kinases. Our laboratory has solved a comprehensive set of crystal structure of this large protein family offering the opportunity to understand molecular mechanisms of their regulation and developing new strategies for their selective targeting. We developed for example a number of highly selective inhibitors by exploring unusual binding modes and allosteric binding sites. A particular focus of the laboratory is also to understand structural mechanisms leading to slow binding kinetics as part of the K4DD consortium.

2022

Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells.

Laux J, Forster M, Riexinger L, Schwamborn A, Guezguez J, Pokoj C, Kudolo M, Berger LM, Knapp S, Schollmeyer D, Guse J, Burnet M, Laufer SA

ACS Pharmacol Transl Sci. 2022-8-12 . 5(8):573-602 .doi: 10.1021/acsptsci.2c00054

PMID: 35983274

A Toolbox for the Generation of Chemical Probes for Baculovirus IAP Repeat Containing Proteins.

Schwalm MP, Berger LM, Meuter MN, Vasta JD, Corona CR, Röhm S, Berger BT, Farges F, Beinert SM, Preuss F, Morasch V, Rogov VV, Mathea S, Saxena K, Robers MB, Müller S, Knapp S

Front Cell Dev Biol. 2022-6-21 . 10:886537 .doi: 10.3389/fcell.2022.886537

PMID: 35721509

Designed Ankyrin Repeat Proteins as a tool box for analyzing p63.

Strubel A, Münick P, Chaikuad A, Dreier B, Schaefer J, Gebel J, Osterburg C, Tuppi M, Schäfer B, Knapp S, Plückthun A, Dötsch V

Cell Death Differ. 2022-6-18 . .doi: 10.1038/s41418-022-01030-y

PMID: 35717504

Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-a]pyrimidine-Based Macrocycles.

Kurz CG, Preuss F, Tjaden A, Cusack M, Amrhein JA, Chatterjee D, Mathea S, Berger LM, Berger BT, Krämer A, Weller M, Weiss T, Müller S, Knapp S, Hanke T

J Med Chem. 2022-5-24 . .doi: 10.1021/acs.jmedchem.2c00173

PMID: 35608370

Calcium/calmodulin-dependent protein kinase kinase 2 regulates hepatic fuel metabolism.

Stork BA, Dean A, Ortiz AR, Saha P, Putluri N, Planas-Silva MD, Mahmud I, Rajapakshe K, Coarfa C, Knapp S, Lorenzi PL, Kemp BE, Turk BE, Scott JW, Means AR, York B

Mol Metab. 2022-5-11 . 101513 .doi: 10.1016/j.molmet.2022.101513

PMID: 35562082

Enabling pseudokinases as potential drug targets.

Preuss F, Chatterjee D, Dederer V, Knapp S, Mathea S

Methods Enzymol. 2022-5-8 . 667:663-683 .doi: 10.1016/bs.mie.2022.03.050

PMID: 35525558

BET bromodomain inhibitors.

Schwalm MP, Knapp S

Curr Opin Chem Biol. 2022-4-21 . 68:102148 .doi: 10.1016/j.cbpa.2022.102148

PMID: 35462054

Synthesis and biological evaluation of Haspin inhibitors: Kinase inhibitory potency and cellular activity.

Zeinyeh W, Esvan YJ, Josselin B, Defois M, Baratte B, Knapp S, Chaikuad A, Anizon F, Giraud F, Ruchaud S, Moreau P

Eur J Med Chem. 2022-4-9 . 236:114369 .doi: 10.1016/j.ejmech.2022.114369

PMID: 35447555

Kinase domain autophosphorylation rewires the activity and substrate specificity of CK1 enzymes.

Cullati SN, Chaikuad A, Chen JS, Gebel J, Tesmer L, Zhubi R, Navarrete-Perea J, Guillen RX, Gygi SP, Hummer G, Dötsch V, Knapp S, Gould KL

Mol Cell. 2022-3-21 . .doi: 10.1016/j.molcel.2022.03.005

PMID: 35353987

Resistance to kinase inhibition through shortened target engagement.

Rangwala AM, Berger BT, Robers MB, Knapp S, Seeliger MA

Mol Cell Oncol. 2022-3-8 . 9(1):2029999 .doi: 10.1080/23723556.2022.2029999

PMID: 35252553